Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
mehreen.datoo@ndm.ox.ac.uk

Research groups

Malaria Programme: Pre-erythrocytic Vaccines

Mehreen Datoo

Clinical Research Fellow and DPhil Student

Recent publications

The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Datoo MS. et al, (2025), Lancet (London, England), 405, 299 - 301
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), The Lancet. Infectious diseases, 24, 465 - 475
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197
"PRIME-TARGET" IMMUNIZATION WITH VIRAL VECTORS FOR ENHANCED EFFICACY OF LIVER-STAGE MALARIA VACCINES
Ewer K. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 585 - 585

More publications